[G22-13] Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Last updated 19.05.2022
Project no.:
G22-13
Commission:
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A21-146 | Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
19-05-2022 A G-BA decision was published.
G-BA documents on this decision